Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett's esophagus

The latest issue of Gastroenterology investigates the use of radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett's esophagus and early esophageal adenocarcinoma.

News image

Patients with Barrett's esophagus and high-grade dysplasia or early neoplasia increasingly receive endoscopic mucosal resection and radiofrequency ablation therapy.

Dr Rehan Haidry and colleagues from the United Kingdom analyzed data from a UK registry that follows the outcomes of patients with Barrett's Esophagus who have undergone resection and radiofrequency ablation for neoplasia.

The research team reported that they collected data on 335 patients with Barrett's esophagus and neoplasia, treated at 19 centers in the United Kingdom from 2008 through 2012.

Mean length of Barrett's esophagus segments was 5.8 cm.

Patients' nodules were removed by endoscopic mucosal resection, and the patients then underwent resection and radiofrequency ablation every 3 months until all areas of Barrett's esophagus were ablated or cancer developed.

The research team collected biopsies for 12 months after the first resection and radiofrequency ablation; clearance of high-grade dysplasia, dysplasia, and Barrett's esophagus were assessed

Symptomatic strictures developed in 9% of patients
Gastroenterology

High-grade dysplasia was cleared from 86% of patients, all dysplasia from 81%, and Barrett's esophagus from 62% at the 12-month time point, after a mean of 2.5 resection and radiofrequency ablation procedures.

The doctors noted that complete reversal dysplasia was 15% less likely for every 1-cm increment in Barrett's esophagus length.

Endoscopic mucosal resection before resection and radiofrequency ablation did not provide any benefit.

Invasive cancer developed in 10 patients by the 12-month time point and disease had progressed in 17 patients after a median follow-up time of 19 months.

The doctors found that symptomatic strictures developed in 9% of patients and were treated by endoscopic dilatation.

The team observed that 19 months after therapy began, 94% of patients remained clear of dysplasia.

Dr Haidry's team commented, "We analyzed data from a large series of patients in the United Kingdom who underwent resection and radiofrequency ablation for Barrett's esophagus-related neoplasia and found that by 12 months after treatment, dysplasia was cleared from 81%. "

"Shorter segments of Barrett's esophagus respond better to resection and radiofrequency ablation."

Gastroenterol 2013: 145(1) 87-95
15 July 2013

Go to top of page Email this page Email this page to a colleague

 26 May 2015

Advanced search
 26 May 2015 
Calcium channel blockers and GI bleeds
 26 May 2015 

Risk factors for celiac disease

 26 May 2015 
Antimicrobials for intraabdominal infection
 25 May 2015 
Risk of GI bleeds with NSAIDs
 25 May 2015 
Colorectal cancer screening
 25 May 2015 
Saccharomyces boulardii and H. pylori
 22 May 2015 
Treatment with anti-integrin antibodies in IBD
 22 May 2015 
Care of patients with GERD
 22 May 2015 
Colonoscopy screening for colorectal cancer
 21 May 2015 
Imaging for hepatocellular carcinoma
 21 May 2015 
Lymphoma in IBD
 21 May 2015 
Serrated polyps and colorectal cancer
 20 May 2015 
Refractory metastatic colorectal cancer
 20 May 2015 
Surveillance in long-segment Barrett's
 20 May 2015 
Pancreatic neuroendocrine tumors
 19 May 2015 
PPIs and cryptogenic liver abscess
 19 May 2015 
Anti-integrin antibodies in IBD
 19 May 2015 
Metabolic syndrome and Barrett's
 18 May 2015 
HLA haplotypes and primary sclerosing cholangitis
 18 May 2015 
Safety of PPI
 18 May 2015 
ESPGHAN celiac guidelines
 15 May 2015 
Management of nonhospitalized ulcerative colitis
 15 May 2015 
Diabetes and infections in IBD with immunomodulation
 15 May 2015 
Microscopic colitis risk with PPIs/NSAIDs
 14 May 2015 
Diagnosis of spontaneous bacterial peritonitis
 14 May 2015 
Mortality in US patients with cirrhosis
 14 May 2015 
Radiation exposure during ERCP
 13 May 2015 
Predictors of IBD
 13 May 2015 
Psychological distress and liver disease mortality
 13 May 2015 
Hypnotherapy in IBS/IBD
 12 May 2015 
Bleeding in NSAID users with H.pylori
 12 May 2015 
Capsule colonoscopy detects colorectal polyps
 12 May 2015 
Anti-TNF biologics in acute severe ulcerative colitis
 11 May 2015 
Management of Barrett's esophagus
 11 May 2015 
Marker to detect recurrence of Crohn's
 11 May 2015 
Thalidomide for IBD
 08 May 2015 
Surveillance colonoscopy in colorectal cancer
 08 May 2015 
HCV treatment with compensated cirrhosis
 08 May 2015 
Medical management of Crohn's
 07 May 2015 
Surgical complications in ulcerative colitis
 07 May 2015 
Combination therapy for noncirrhostic patients
 07 May 2015 
Anxiety and new-onset dyspepsia
 06 May 2015 
PPIs and spontaneous bacterial peritonitis
 06 May 2015 
Infant feeding and celiac disease
 06 May 2015 
Preventing recurrent C. diff infection
 05 May 2015 
Fatigue in primary sclerosing cholangitis
 05 May 2015 
Annual CT scans after esophagectomy for cancer
 05 May 2015 
Prevalence of eosinophilic esophagitis
 04 May 2015 
Stress resilience and peptic ulcer disease
 04 May 2015 
Endoscope storage and microbial colonization
 04 May 2015 
Menarche and NAFLD
 01 May 2015 
Sleep and physical activity measured in Crohn's
 01 May 2015 
NAFLD progression from steatosis to fibrosing-steatohepatitis
 01 May 2015 
Dietary supplement hepatotoxicity
 30 April 2015 
Risk factors for primary sclerosing cholangitis
 30 April 2015 
Neoadjuvant chemoradiotherapy for esophageal cancer
 30 April 2015 
Botulinum toxin A for the treatment of obesity
 29 April 2015 
Hepatocellular carcinoma surveillance in HBV
 29 April 2015 
Liver enzyme elevations after anti-TNF therapy in IBD

 29 April 2015 
Response to sorafenib in hepatocellular carcinoma

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us